Why the study?
Does acetylcysteine prevent acute doxorubicin-induced myocardial morphologic damage in patients with normal cardiovascular function?
Population
20 patients with normal cardiovascular function receiving doxorubicin
Comparison
Acetylcysteine administered 1 hour before… vs Placebo administered 1 hour before doxorubicin
Design
RCT, randomized to 2 groups based on age and dose of doxorubicin
Follow-up
24 hours
Authors
Loading...
Acetylcysteine should not be used to prevent acute doxorubicin myocardial damage; confirms null effect on morphology in RCT.
Does acetylcysteine prevent acute doxorubicin-induced myocardial morphologic damage in patients with normal cardiovascular function?
Prophylactic administration of acetylcysteine does not prevent acute doxorubicin-induced myocardial morphologic damage.
Unverferth et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: